Dedifferentiated Liposarcoma
18
4
7
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
16.7%
3 terminated out of 18 trials
57.1%
-29.4% vs benchmark
6%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (18)
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Study of Abemaciclib in Dedifferentiated Liposarcoma
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
First-line Treatment of Advanced/unresectable DDLPS
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Selinexor in Advanced Liposarcoma
Ph II Cabazitaxel DD Liposarcoma
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma